Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia.
[waldenström macroglobulinemia]
Bortezomib
frequently
produces
severe
treatment-related
peripheral
neuropathy
(
PN
)
in
Waldenström
's
macroglobulinemia
(
WM
)
.
Carfilzomib
is
a
neuropathy
-sparing
proteasome
inhibitor
.
We
examined
carfilzomib
,
rituximab
,
and
dexamethasone
(
CaRD
)
in
symptomatic
WM
patients
naïve
to
bortezomib
and
rituximab
.
Protocol
therapy
consisted
of
intravenous
carfilzomib
,
20
mg
/
m
2
(
cycle
1
)
and
36
mg
/
m
(
2
)
(
cycles
2
-
6
)
,
with
intravenous
dexamethasone
,
20
mg
,
on
days
1
,
2
,
8
,
and
9
,
and
rituximab
,
375
mg
/
m
(
2
)
,
on
days
2
and
9
every
21
days
.
Maintenance
therapy
followed
8
weeks
later
with
intravenous
carfilzomib
,
36
mg
/
m
(
2
)
,
and
intravenous
dexamethasone
,
20
mg
,
on
days
1
and
2
,
and
rituximab
,
375
mg
/
m
(
2
)
,
on
day
2
every
8
weeks
for
8
cycles
.
Overall
response
rate
was
87
.
1
%
(
1
complete
response
,
10
very
good
partial
responses
,
10
partial
responses
,
and
6
minimal
responses
)
and
was
not
impacted
by
MYD
88
(
L
265
P
)
or
CXCR
4
(
WHIM
)
mutation
status
.
With
a
median
follow-up
of
15
.
4
months
,
20
patients
remain
progression
free
.
Grade
≥
2
toxicities
included
asymptomatic
hyperlipasemia
(
41
.
9
%
)
,
reversible
neutropenia
(
12
.
9
%
)
,
and
cardiomyopathy
in
1
patient
(
3
.
2
%
)
with
multiple
risk
factors
,
and
PN
in
1
patient
(
3
.
2
%
)
which
was
grade
2
.
Declines
in
serum
IgA
and
IgG
were
common
.
CaRD
offers
a
neuropathy
-sparing
approach
for
proteasome
inhibitor-based
therapy
in
WM
.
This
trial
is
registered
at
www
.
clinicaltrials
.
gov
as
#
NCT
01470196
.
Diseases
Validation
Diseases presenting
"peripheral neuropathy"
symptom
adrenomyeloneuropathy
esophageal squamous cell carcinoma
hodgkin lymphoma, classical
homocystinuria without methylmalonic aciduria
kallmann syndrome
krabbe disease
neuralgic amyotrophy
oculocutaneous albinism
pyruvate dehydrogenase deficiency
sneddon syndrome
systemic capillary leak syndrome
thoracic outlet syndrome
triple a syndrome
waldenström macroglobulinemia
x-linked adrenoleukodystrophy
zellweger syndrome
This symptom has already been validated